Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Adriano Venditti, Jing-Zhou Hou, Pierre Fenaux, Brian A. Jonas, Radovan Vrhovac, Pau Montesinos, Jacqueline S. Garcia, David Rizzieri, Michael J Thirman, Stanley Kotey, Jalaja Potluri, Mazaher Dhalla, Vinod Pullarkat

Blood (2023) 142 (Supplement 1): 2886.

https://doi.org/10.1182/blood-2023-182045

Published: 2023

Journal Articles

Assessing Adoption of Standard of Care and Comparing Clinical and Demographic Differences in First-Line (1L) Treatment (Tx) of Chronic Lymphocytic Leukemia (CLL)

Jing-Zhou Hou, Michael Gart, Anupama Vasudevan, Harvey I. Katzen, Rushir Choksi, Simon Blanc

Blood (2023) 142 (Supplement 1): 130.

https://doi.org/10.1182/blood-2023-178685

Published: 2023

Journal Articles

Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-Cell Engager (TCE): Updated Safety and Efficacy Data from the Ongoing First-in-Human (FIH) Phase 1 Trial

Sameh Gaballa, Ranjit Nair, Ryan W Jacobs, Sumana Devata, Seok-Goo Cho, Don A. Stevens, Dok Hyun Yoon, Nirav N. Shah, Denise Brennan, Jason Law, Robert Chen, David Sermer, Robin Lesley, Ben Buelow, Alessandra Forcina, Jing-Zhou Hou

Blood (2023) 142 (Supplement 1): 1662.

https://doi.org/10.1182/blood-2023-174668

Published: 2023

Journal Articles

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices

Jing-Zhou Hou, Simon Blanc, Gregory A Maglinte, Anupama Vasudevan, Anna Rui, Michael Gart, Hoa Pham, Lindsay Aton, Brandon Wang, Rushir Choksi

Blood (2023) 142 (Supplement 1): 5163.

https://doi.org/10.1182/blood-2023-174915

Published: 2023

Journal Articles

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Blood (2022) 140 (25): 2754–2756.

https://doi.org/10.1182/blood.2022016963

Published: 2022

Includes: Supplemental data

Journal Articles

Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A

Adriano Venditti, Jing-Zhou Hou, Pierre Fenaux, Brian A. Jonas, Radovan Vrhovac, Pau Montesinos, Jacqueline S. Garcia, David Rizzieri, Michael J. Thirman, Melissa Montez, Yingyi Liu, John Katsetos, Jalaja Potluri, Catherine Miller, Vinod A. Pullarkat

Blood (2022) 140 (Supplement 1): 8993–8995.

https://doi.org/10.1182/blood-2022-158500

Published: 2022

Journal Articles

Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL

Jing-Zhou Hou, Ryan Jacobs, Seok-Goo Cho, Sumana Devata, Sameh Gaballa, Dok Hyun Yoon, Don A. Stevens, Jin Seok Kim, Ben Buelow, Ranjit Nair

Blood (2022) 140 (Supplement 1): 1474–1475.

https://doi.org/10.1182/blood-2022-166385

Published: 2022

Journal Articles

Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1 st Induction Regimen

Konstantinos Lontos, Robert L. Redner, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic J. Farah, Annie Im, Kathleen Dorritie, Alison R. Sehgal, James M. Rossetti, Daniel Normolle, Michael M. Boyiadzis

Blood (2022) 140 (Supplement 1): 6145–6146.

https://doi.org/10.1182/blood-2022-156468

Published: 2022

Journal Articles

Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study

Blood (2021) 138 (Supplement 1): 369.

https://doi.org/10.1182/blood-2021-150371

Published: 2021

Journal Articles

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Anastasia Tsagianni, MD, Konstantinos Lontos, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic J. Farah, MD, Robert L. Redner, MD, Annie Im, MD, Kathleen A. Dorritie, MD, Alison R. Sehgal, MD, James M. Rossetti, DO, Melissa Saul, MS, William Gooding, MS, Michael Boyiadzis, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138561

Published: 2020

Journal Articles

Dose Reductions and Discontinuations with Chronic Lymphocytic Leukemia (CLL) Patients Receiving Ibrutinib in Community and Academic Settings

Jing-Zhou Hou, MD PhD, Kellie Ryan, MPH, Senxi Du, Bruno S. Fang, MD, Stanley M. Marks, MD, Ray Page, Eileen Peng, PharmD, Keith Szymanski, Sharon Winters, Hannah Le, PharmD, MPH

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-139951

Published: 2020

Journal Articles

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Blood (2020) 135 (24): 2137–2145.

https://doi.org/10.1182/blood.2020004856

Published: 2020

Includes: Supplemental data

Journal Articles

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Asha Ricciuti, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic Farah, MD, Robert L. Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, James M. Rossetti, DO, Yongli Shuai, PhD, Daniel Normolle, PhD, Rahim Remtulla, MD, Shawn Tahata, MD, Michael Boyiadzis, MD, Annie Im, MD

Blood (2018) 132 (Supplement 1): 4000.

https://doi.org/10.1182/blood-2018-99-113935

Published: 2018

Journal Articles

Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy

Andrew Wei, MD, Stephen A. Strickland, MD, Jing-Zhou Hou, MD PhD, Walter Fiedler, MD, Tara L Lin, MD, Roland B. Walter, MDPhDMS, Anoop K Enjeti, MBBS,FRCPA,MDMRCP, Wan-Jen Hong, Brenda Chyla, Relja Popovic, PhD, Kaffa Fakouhi, Tu Xu, PhD, John Hayslip, Gail J. Roboz, MD

Blood (2018) 132 (Supplement 1): 284.

https://doi.org/10.1182/blood-2018-99-118729

Published: 2018

Journal Articles

Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes

Andrew Wei, MBBS, PhD FRACP, FRCPA, Stephen A. Strickland, MD MSCI, Gail J. Roboz, MD, Jing-Zhou Hou, MD PhD, Walter Fiedler, MD, Tara L. Lin, MD, Roland B. Walter, MD PhD, Anoop Enjeti, MD MRCP, FRCPA, MClin Epid, GradCert Bioethics, Brenda Chyla, PhD, Relja Popovic, PhD, Kaffa Fakouhi, Pooja Shah, Martin Dunbar, DRPH, MS, Tu Xu, PhD, Mack Mabry, MD, John Hayslip, MD MSCR

Blood (2017) 130 (Supplement 1): 890.

https://doi.org/10.1182/blood.V130.Suppl_1.890.890

Published: 2017

Journal Articles

Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study

Gilles A. Salles, Judith Trotman, MB ChB, Michael Lill, MD BS, Bruce Cheson, MD, Stephen J. Schuster, MD, Jing-Zhou Hou, John A Radford, MB ChB, MRCP, MD FRCP, Andrew Spencer, Michael Schaffer, PhD, Rajendra Damle, PhD, Gary J. Gartenberg, MD, Jessica Vermeulen, MD PhD, Sriram Balasubramanian, PhD, Sanjay Deshpande, MD, Dolores Caballero, MD PhD

Blood (2016) 128 (22): 2980.

https://doi.org/10.1182/blood.V128.22.2980.2980

Published: 2016

Journal Articles

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Michael Boyiadzis, MD MHSc, Mounzer Agha, MD, Robert L Redner, MD, Alison Sehgal, MD, Annie Im, MD, Jing-Zhou Hou, Rafic Farah, MD, Kathleen A. Dorritie, MD, Anastasios Raptis, MD PhD, Seah H. Lim, MDPhDFRCP,FRCPath,MBBS, Hans Klingemann, MD PhD, Hong Wang, PhD, Natalia Lapteva, PhD, Mei Zhuyong, MD, Lisa H Butterfield, PhD, Cliona M. Rooney, PhD, Theresa L Whiteside, PhD

Blood (2016) 128 (22): 1649.

https://doi.org/10.1182/blood.V128.22.1649.1649

Published: 2016

Journal Articles

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia

Andrew Wei, Stephen A. Strickland, Gail J. Roboz, Jing-Zhou Hou, Walter Fiedler, MD, Tara L. Lin, Giovanni Martinelli, Roland B. Walter, MD PhD, Anoop Enjeti, Kaffa Fakouhi, David E. Darden, Martin Dunbar, Ming Zhu, Suresh Agarwal, Ahmed H. Salem, Mack Mabry, John Hayslip

Blood (2016) 128 (22): 102.

https://doi.org/10.1182/blood.V128.22.102.102

Published: 2016

Journal Articles

Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study

Ajay K. Gopal, MD, Stephen J. Schuster, MD, Nathan Fowler, MD, Judith Trotman, MBChB, Georg Hess, MD, Jing-Zhou Hou, Abdulraheem Yacoub, MD, Michael Lill, MD BS, Peter Martin, MD, Umberto Vitolo, MD, Wojciech Jurczak, MD, James Morton, MBBS, BSc(MD, FRACP, FRCPA, Dzhelil Osmanov, MD, Gary J. Gartenberg, MD, Jessica Vermeulen, MD PhD, Sriram Balasubramanian, PhD, Shean-sheng Wang, PhD, Sanjay Deshpande, MD, Gilles A. Salles

Blood (2016) 128 (22): 1217.

https://doi.org/10.1182/blood.V128.22.1217.1217

Published: 2016

Journal Articles

Phase 2 Study of Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Annie Im, MD, Mounzer Agha, MD, Anastasios Raptis, MD PhD, Jing-Zhou Hou, MD PhD, Rafic Farah, MD, Seah H. Lim, MDPhDFRCP,FRCPath,MBBS, Robert Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, Ann Welsh, RN, BSN, OCN, Linda Fukas, RN, Christine Tripoli, RN, BSN, Daniel Normolle, PhD, Daniel E Johnson, PhD, Michael Boyiadzis, MD MHSc

Blood (2015) 126 (23): 3739.

https://doi.org/10.1182/blood.V126.23.3739.3739

Published: 2015

NARROW

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Assessing Adoption of Standard of Care and Comparing Clinical and Demographic Differences in First-Line (1L) Treatment (Tx) of Chronic Lymphocytic Leukemia (CLL)

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A

Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL

Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1 st Induction Regimen

Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Dose Reductions and Discontinuations with Chronic Lymphocytic Leukemia (CLL) Patients Receiving Ibrutinib in Community and Academic Settings

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy

Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes

Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia

Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study

Phase 2 Study of Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only